Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lobaplatin neoadjuvant intravesical therapy for high-risk NMIBC
ChiCTR2400084752Phase 4Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- May 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lobaplatin in non-muscle-invasive bladder cancer (NMIBC), sponsored by Tongji Hospital. Primary endpoints: Bladder-preserving treatment rate, Treatment-related adverse reactions and 1 more. Planned start May 2024; status: not yet recruiting.
02
Drugs
lobaplatin
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on ChiCTR2400084752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084752.